Merck (MRK) Liabilities and Shareholders Equity (2009 - 2026)

Merck (MRK) has reported Liabilities and Shareholders Equity for 18 consecutive years, with $129.8 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 10.45% year-over-year to $129.8 billion in Q2 2026; TTM through Jun 2026 was $524.9 billion, a 12.33% increase from a year earlier, with the FY2025 full-year figure at $136.9 billion, up 16.87% from the prior year.
• Liabilities and Shareholders Equity was $129.8 billion for Q2 2026 at Merck, up from $128.7 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $136.9 billion in Q4 2025 and troughed at $104.5 billion in Q2 2023.
• A 5-year average of $114.8 billion and a median of $110.9 billion in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity gained 18.09% in 2022 and fell 2.45% in 2023, its largest moves.
• Over 5 years, Liabilities and Shareholders Equity stood at $109.2 billion in 2022, then fell by 2.28% to $106.7 billion in 2023, then rose by 9.78% to $117.1 billion in 2024, then rose by 16.87% to $136.9 billion in 2025, then retreated by 5.16% to $129.8 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $129.8 billion (Q2 2026), $128.7 billion (Q1 2026), and $136.9 billion (Q4 2025), per Business Quant data.